Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before starting any weight loss program.
Tirzepatide — marketed as Mounjaro — has generated more clinical interest than almost any other obesity medication in the past decade. Its dual mechanism targets two separate gut-hormone receptors, producing weight loss outcomes that consistently outperform older GLP-1 therapies in head-to-head and placebo-controlled trials. For Australians navigating the growing landscape of weight management options, understanding where tirzepatide sits — in terms of evidence, access, and cost — is increasingly important.
This guide covers the mechanism, the clinical data, the current regulatory and access situation in Australia, and who is most likely to benefit.
Tirzepatide is a once-weekly injectable peptide that acts as a dual agonist at two receptors: the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. This dual action is what distinguishes it from earlier GLP-1 medications such as semaglutide, which targets only the GLP-1 receptor.
GIP is a gut hormone released in response to nutrient ingestion, particularly carbohydrates and fats. In metabolic health, GIP plays several roles: it enhances insulin secretion, promotes fat storage in adipose tissue, and may modulate satiety signalling in the brain. The exact contribution of GIP agonism to tirzepatide's weight loss effect is still being studied, but current evidence suggests it amplifies the effects of GLP-1 signalling rather than acting independently.
Like semaglutide, tirzepatide activates GLP-1 receptors in the gut, pancreas, and brain. This drives:
Together, these mechanisms produce substantial reductions in caloric intake and improvements in metabolic markers including fasting glucose, HbA1c, blood pressure, and lipids.
The SURMOUNT clinical programme is the primary evidence base for tirzepatide in obesity. The trials enrolled adults with a body mass index of 30 or above, or 27 or above with at least one weight-related comorbidity.
SURMOUNT-1 was a 72-week, randomised, placebo-controlled trial involving 2,539 adults without type 2 diabetes. Participants received one of three doses — 5 mg, 10 mg, or 15 mg weekly — or placebo.
Key findings at 72 weeks:
In the 15 mg group, roughly one in three participants lost more than 25% of their body weight — an outcome previously associated only with bariatric surgery in most clinical settings.
SURMOUNT-2 evaluated tirzepatide in adults with obesity and type 2 diabetes. Weight loss was somewhat lower in this population (reflecting the known attenuating effect of diabetes pharmacotherapy on body weight), but still clinically meaningful: approximately 13.4% at the 15 mg dose compared to 3.3% with placebo.
SURMOUNT-4 examined what happens when tirzepatide is discontinued. Participants who lost weight during an initial treatment phase and then switched to placebo regained a substantial proportion of that weight over the following year. This aligns with evidence from semaglutide withdrawal studies and confirms that tirzepatide, like other GLP-1 class medications, requires ongoing use to maintain its effects.
The question most patients and clinicians ask is how tirzepatide compares to semaglutide (Ozempic at 1 mg for diabetes, Wegovy at 2.4 mg for obesity). For a detailed head-to-head comparison, see our article on tirzepatide vs semaglutide in Australia.
In brief:
For background on the broader GLP-1 landscape and what makes these medications different from lifestyle intervention alone, the tirzepatide research overview from RetaLABS provides useful mechanistic context on how this class of compounds operates at a molecular level.
As of 2026, the Therapeutic Goods Administration (TGA) has approved tirzepatide (Mounjaro) in Australia for both type 2 diabetes management and chronic weight management in adults. This means the medication can be legally prescribed by Australian doctors and dispensed by Australian pharmacies.
TGA approval does not, however, automatically mean cost subsidisation through the Pharmaceutical Benefits Scheme (PBS).
Tirzepatide is not PBS-listed in Australia as of mid-2026. It is available only on private prescription, meaning patients pay the full cost out of pocket. This is a significant financial barrier for most Australians — a factor that distinguishes the Australian access situation from some other countries.
For context on PBS obesity treatment policy and what reforms are being discussed, see our article on the Wegovy PBS listing in Australia, which covers the broader access policy environment. Advocacy for improved PBS coverage of obesity medications is ongoing — the discussion around Medicare and PBS obesity treatment reform reflects why access policy in this area remains contested and why reform is needed.
Private prescription costs for tirzepatide in Australia vary by dose and pharmacy, but patients should expect to pay in the range of $350–$500 per month for a standard maintenance dose. These figures can fluctuate based on:
It is important to note that compounded tirzepatide, while sometimes available at lower cost, is not subject to the same quality controls as TGA-approved Mounjaro. Patients should discuss the distinction with their prescribing doctor.
To obtain a private prescription for Mounjaro in Australia, patients need to:
Telehealth obesity medicine services have made prescriber access more geographically equitable, though the cost of the medication itself remains the primary barrier.
Based on current clinical evidence and prescribing guidance, tirzepatide is most appropriate for adults who:
Tirzepatide is not currently indicated for weight loss in individuals below the BMI thresholds above, or in those whose primary goal is performance or cosmetic body composition change.
For patients with both obesity and type 2 diabetes, tirzepatide has a dual clinical benefit — weight reduction and improved glycaemic control. In the SURPASS clinical programme (focused on diabetes management), tirzepatide demonstrated HbA1c reductions of 1.8–2.1 percentage points, making it one of the most effective glucose-lowering agents currently available.
The most frequently reported side effects are gastrointestinal and are most pronounced during dose escalation:
Most gastrointestinal side effects improve over time and are managed by slow dose titration. The standard approach starts at 2.5 mg weekly for four weeks before escalation.
Patients on tirzepatide typically require:
Tirzepatide is administered via a prefilled, single-use pen injector. Injections are subcutaneous — typically in the abdomen, thigh, or upper arm. Most patients find the process straightforward after the first dose.
Mounjaro pens require refrigeration at 2–8 degrees Celsius. They can be kept at room temperature (below 30 degrees Celsius) for up to 21 days, which is practical for travel. Australia's warm climate makes storage management more relevant than in cooler countries.
Clinical trials of tirzepatide were conducted alongside lifestyle counselling — diet and exercise guidance. The medication works best when combined with meaningful dietary changes and regular physical activity. Weight loss outcomes in real-world settings without lifestyle support may be less dramatic than those observed in trial conditions.
The Australian government's treatment of obesity medications under the PBS has been a significant area of advocacy. Currently, no obesity-specific GLP-1 medication is PBS-subsidised for weight management alone — coverage applies only to type 2 diabetes management. The cost burden means that access to these medications is largely confined to patients who can afford private prescription costs, creating a meaningful inequality in care.
Applications to the Pharmaceutical Benefits Advisory Committee (PBAC) for tirzepatide are anticipated. The outcome will depend on cost-effectiveness modelling, budget impact assessments, and the committee's view of the clinical benefit relative to existing therapies.
For Australians following the access policy landscape, the PBS situation for Mounjaro is likely to evolve materially over the next two years.
Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist with the strongest weight loss efficacy data of any pharmacological agent currently available. SURMOUNT trial results show average weight reductions of up to approximately 22.5% of body weight at the 15 mg dose — results that approach bariatric surgery outcomes in some individuals. In Australia, the medication is TGA approved but not PBS listed, meaning private prescription costs of $350–$500 per month are the primary barrier to access. It is an appropriate option for adults with BMI 30 or above, or BMI 27 or above with comorbidities, who have not responded adequately to lifestyle intervention. Like all GLP-1 class medications, tirzepatide requires ongoing use to maintain its effects. As access policy evolves and PBS applications proceed, the Australian tirzepatide landscape is expected to shift.
A research-backed explainer on orforglipron (Foundayo) — the first oral small-molecule GLP-1 receptor agonist approved for weight loss, why no-restriction dosing matters, what the ATTAIN trials showed, and how it compares to injectables and oral semaglutide.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.
Why weight loss plateaus happen: adaptive thermogenesis, NEAT decline, leptin changes, the Biggest Loser study, and strategies to break through.